Nowarta110 for COVID-19
COVID-19
IND FiledActive
Key Facts
About Nowarta Biopharma
Nowarta Biopharma is a private, pre-revenue biotech founded in 2020, advancing a novel botanical drug candidate, Nowarta110, through clinical development. The company's lead program targets HPV-induced plantar warts, having demonstrated a 64.3% complete lesion clearance rate with zero serious adverse events in a Phase I/II study, with a Phase 3 trial planned for 2026. Nowarta is pursuing an ambitious pipeline expansion into cervical dysplasia (CIN 2,3), COVID-19, and skin cancers, leveraging regulatory designations like Fast Track, though its early-stage and broad focus present significant development and execution risks.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |